Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Not seeking treatment for drugs of abuse~* Diagnostic and Statistical Manual of Mental Disorders-IV diagnosis of cocaine dependence (not applicable for individuals enrolling as healthy controls)~* Positive urine drug screen test for cocaine (not applicable for individuals enrolling as healthy controls)~* Females must use adequate forms of contraception throughout the study~* Stable residence for the 30 days prior to enrollment~* No history of N-acetylcysteine within the 7 days prior to enrollment~* Nicotine smokers staying at the inpatient unit must use the nicotine patch during inpatient stay~Exclusion Criteria:~* Dependence on any psychoactive substance other than alcohol, nicotine, or marijuana; control subjects cannot be dependent on cocaine~* Need for medication detoxification for alcohol~* History of psychiatric disorders, including depression, bipolar disorder, post traumatic stress disorder, dementia, and organic brain disorder~* Suicidal or homicidal behavior within the 30 days prior to enrollment~* History of psychotic symptoms, including those observed during cocaine use~* History of serious medical illness, including cardiovascular disease, angina, myocardial infarction, liver disease, and kidney disease~* History of neurologic, metabolic, neoplastic, nutritional, inflammatory, or endocrine disorders~* Court requirement to receive treatment~* Expecting elective surgery within the 5 weeks prior to enrollment~* Known hypersensitivity to N-acetylcysteine~* Use of antidepressants (such as selective serotonin reuptake inhibitors or tricyclics), dopamine agonists, or psychotropic medications (such as anticonvulsants, antipsychotics, anxiolytics, or psychostimulants) within the 14 days prior to enrollment~* Pregnant or breastfeeding~* History of asthma~* History of seizures~* Participation in treatment for cocaine abuse within the 30 days prior to enrollment~* Lactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): Identical appearing placebo pill containing lactose powder, packaged to have similar odor as N-Acetylcysteine in capsule form
- 1 (Type: EXPERIMENTAL): N-Acetylcysteine

Based on this trial design, predict the completion outcome and termination type (if applicable).